Advances and challenges in the treatment of esophageal cancer

Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shiming He, Jian Xu, Xiujun Liu, Yongsu Zhen
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Drug combination Esophageal adenocarcinoma Esophageal squamous cell carcinoma Immune therapy Molecular targeted therapy Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/9eca37b54fe44c4b85dd7c58d9a19ab3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9eca37b54fe44c4b85dd7c58d9a19ab3
record_format	dspace
spelling	oai:doaj.org-article:9eca37b54fe44c4b85dd7c58d9a19ab32021-12-02T05:01:20ZAdvances and challenges in the treatment of esophageal cancer2211-383510.1016/j.apsb.2021.03.008https://doaj.org/article/9eca37b54fe44c4b85dd7c58d9a19ab32021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2211383521000794https://doaj.org/toc/2211-3835Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries. The currently available treatment strategies for EC include surgery, chemotherapy, radiation therapy, molecular targeted therapy, and combinations thereof. However, the prognosis remains poor, and the overall five-year survival rate is very low. Therefore, achieving the goal of effective treatment remains challenging. In this review, we discuss the latest developments in chemotherapy and molecular targeted therapy for EC, and comprehensively analyze the application prospects and existing problems of immunotherapy. Collectively, this review aims to provide a better understanding of the currently available drugs through in-depth analysis, promote the development of new therapeutic agents, and eventually improve the treatment outcomes of patients with EC.Shiming HeJian XuXiujun LiuYongsu ZhenElsevierarticleDrug combinationEsophageal adenocarcinomaEsophageal squamous cell carcinomaImmune therapyMolecular targeted therapyTherapeutics. PharmacologyRM1-950ENActa Pharmaceutica Sinica B, Vol 11, Iss 11, Pp 3379-3392 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Drug combination Esophageal adenocarcinoma Esophageal squamous cell carcinoma Immune therapy Molecular targeted therapy Therapeutics. Pharmacology RM1-950
spellingShingle	Drug combination Esophageal adenocarcinoma Esophageal squamous cell carcinoma Immune therapy Molecular targeted therapy Therapeutics. Pharmacology RM1-950 Shiming He Jian Xu Xiujun Liu Yongsu Zhen Advances and challenges in the treatment of esophageal cancer
description	Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries. The currently available treatment strategies for EC include surgery, chemotherapy, radiation therapy, molecular targeted therapy, and combinations thereof. However, the prognosis remains poor, and the overall five-year survival rate is very low. Therefore, achieving the goal of effective treatment remains challenging. In this review, we discuss the latest developments in chemotherapy and molecular targeted therapy for EC, and comprehensively analyze the application prospects and existing problems of immunotherapy. Collectively, this review aims to provide a better understanding of the currently available drugs through in-depth analysis, promote the development of new therapeutic agents, and eventually improve the treatment outcomes of patients with EC.
format	article
author	Shiming He Jian Xu Xiujun Liu Yongsu Zhen
author_facet	Shiming He Jian Xu Xiujun Liu Yongsu Zhen
author_sort	Shiming He
title	Advances and challenges in the treatment of esophageal cancer
title_short	Advances and challenges in the treatment of esophageal cancer
title_full	Advances and challenges in the treatment of esophageal cancer
title_fullStr	Advances and challenges in the treatment of esophageal cancer
title_full_unstemmed	Advances and challenges in the treatment of esophageal cancer
title_sort	advances and challenges in the treatment of esophageal cancer
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/9eca37b54fe44c4b85dd7c58d9a19ab3
work_keys_str_mv	AT shiminghe advancesandchallengesinthetreatmentofesophagealcancer AT jianxu advancesandchallengesinthetreatmentofesophagealcancer AT xiujunliu advancesandchallengesinthetreatmentofesophagealcancer AT yongsuzhen advancesandchallengesinthetreatmentofesophagealcancer
_version_	1718400844481691648

Advances and challenges in the treatment of esophageal cancer

Ejemplares similares